UroToday - Conference Coverage

Additional References
Friday, 14 April 2006
read more

#116
Friday, 14 April 2006
Measurement of Penile Curvature in Peyronie's Disease Patients: Correlation between Intracavernosal Injection, Vacuum Device and at-Home Photography Ohebshalom, M; Guhring, P; Mulhall, JP Introduction: The magnitude of penile curvamre in men with Peyronie's disease is a determinant of ability to participate in penetrative sexual relations and may impact upon choice of surgical therapy if required. In this study we examined the concordance between 3 commonly used methods ofpeni]e curvature measurement, namely intracavernosa] injection (ICI), vacuum device (VD) and at-home photography (AHP).
read more

#96
Friday, 14 April 2006
New in the Pathogenesis of Peyronies's Disease Mazo E; Ivanchenko, L; Moufagued, M (presented by: Evsey Mazo, PhD, DMSc, Professor) Introduction: Formation of the plaques in PD is a multifactorial process, incorporating numerous genetic, structural and immune events, causes of which still are not precisely identified. Because of this, management of the disease remains controversial. Aim of the Study: to evaluate results of virological (virus herpes simplex type I, II, cytomegalovirus) and immunological assessment of patients with PD.
read more

#74
Friday, 14 April 2006
Avanafil Is a Highly Selective Phosphodiesterase-5 Inhibitor and Has the Potential for the Treatment of Erectile Dysfunction Kotera, J1; Mochida, H1; Inoue, H1; Noto, T1; Yano, K1; Fujishige, K1; Sasaki, T1; Kobayashi, T1; Tikkawa, K1; Omori, K1 1: Tanabe Seiyaku Co., Ltd., Saitama, Japan Introduction and Objectives: Eleven cyclic nucleotide phosphodiesterase (PDE) families regulate cellular functions via cyclic nucleotide signaling. In penile erection mediated by cGMP signaling, cGMPhydrolyzing PDE, PDE5, functions as a terminator of the signaling. Selective PDE5 inhibition is essential for treatment of the disease. Here we show inhibitory effects of avanafil (TA-1790, a novel PDE5 inhibitor), sildenafil, vardenafil, and tadalafil on 11 PDEs. Avanafil is highly selective to PDE5 and shows the potentiation of penile tumescence in anesthetized dogs.
read more

#73
Friday, 14 April 2006
Vasoprotective Pattern of Gene Expression in Human Penile Smooth Muscle Cells Following Biaxial Stretch King, SH; Chitaley, K; Engel, KL; Sullivan, CJ; Wessells, H (Presented by: Steven H. King, MD) Introduction and Objectives: At the time of maximal erection, flow is decreased to basal levels and intracavernosal pressure is elevated significantly, resulting in stretch of the cavernosal sinusoids. Stretch of the penile smooth muscle cells (SMCs) may not be simply a passive event, but may also be important for the maintenance of SMC homeostasis through the regulation of gene expression. Indeed, stretch responsive SMC genes have been identified in the human bladder and in other vascular tissues. We hypothesized that repeated cycles of sustained stretch, as relevant to the physiologic mechanism of nocturnal tumescence, induce gene expression of pro-erectile, vasoprotective growth factors.
read more

#72
Friday, 14 April 2006
Diabetes Mellitus Is a Risk Factor for Increased Severity of Peyronie's Disease: a Comparative Clinical Study Kendirci, M1; Trost, L1; Sikka, SC1; Hellstrom, WJG1 1: Tulane University, School of Medicine, Department of Urology, New Orleans/LA Introduction and Objectives: Both diabetes mellitus (DM) and Peyronie's disease are associated with an abnormal extracellular matrix composition in the penis. The clinical relationship between DM and PD is undocumented. The aim of this study was to evaluate the severity of penile deformity and penile blood flow parameters in PD patients with DM only and PD patients without any risk factors.
read more

#71
Friday, 14 April 2006
Gene-Modified ex vivo Expanded Marrow Stromal Cell Transfer for Gene Therapy of Erectile Dysfunction in Diabetic Rats Kendirci, M1; Deng, W2; Bivalacqua, TJ3; Kadowitz, PJ2; Hellstrom, WJG1 1: Department of Urology; 2: Department of Pharmacology, Tulane University Health Sciences Center, New Orleans/LA; 3: Johns Hopkins Hospital Department of Urology, Baltimore/MD Introduction and Objectives: Diabetes is associated with decreased nitric oxide synthase (NOS) activity and NO bioavailability, thereby contributing to erectile dysfunction (ED). We have previously demonstrated that adenoviral gene transfer of endothelial NOS (Ad-eNOS) partially restored erectile function in diabetic rats. The aim of this study was to investigate the effect of eNOS-gene-modified ex vivo expanded marrow stromal cell transfer on erectile function in an animal model of diabetes.
read more

#70
Friday, 14 April 2006
Cavernosal Neuroprotection with Ino-1001 in a Rat Model of Postprostatectomy Erectile Dysfunction Kendirci, M1; Zsengeller, Z1; Szabo, C1; Hellstrom, WJG1 1: Tulane University, School of Medicine, Department of Urology, New Orleans/LA Introduction and Objectives: Poly(ADP-ribose) polymerase (PARP) activation during neuronal injury plays a role in the development of neurotoxicity and neurodegenerative disorders. PARP inhibitors have been shown to exert protective effects in stroke, neurotrauma and diabetic neuropathy. The role of the PARP pathway in the pathogenesis of neurogenic erectile dysfunction (ED) has not been researched. The aim of this study was to investigate the effects of PARP activation on erectile function following cavernous nerve injury and to evaluate the neuroprotective effects ofINO-1001 (a PARP inhibitor) in a rat model of cavernous nerve injury.
read more

#69
Friday, 14 April 2006
Testosterone Replacement Therapy for Prostate Cancer Patients with Symptomatic Severe Hypogonadism After Luteinizing Hormone-Releasing Hormone Agonist Prior to Radiotherapy Kaufman, JM1 1: Urology Research Options, Aurora, CO It has been increasingly common to administer luteinizing hormonereleasing hormone (LH-RH) agonists prior to radiotherapy (RT) for prostate cancer. Even short courses of LH-RH agonists can result in a severe, prolonged symptomatic hypogonadism. Based on the assumption that being eugonadal is not detrimental to prostate cancer, prostate cancer patients severely hypogonadal after LH-RH agonist therapy prior to RT were cautiously treated with topical testosterone(T).
read more

#68
Friday, 14 April 2006
Safety and Efficacy of Avanafil, A New PDES Inhibitor for Treating Erectile Dysfunction Kaufman, J1; Aurora, CO1 1: John Dietrich, Mountain View, CA
read more

#67
Friday, 14 April 2006
Rhoa/Rho-Kinase: A Molecular Target for the Treatment of Age-Associated Erectile Dysfunction Jin, L1*; Liu, T1*; Bivalacqua, TJ1; Lagoda, GA1; Burnett, AL1 *Co-first authors. 1: Department of Urology, Johns Hopkins University, Baltimore, MD Introduction and Objectives: Epidemiologic smdies have shown that aging accounts significantly for the prevalence of erectile dysfunction (ED). The underlying molecular mechanisms of ED during aging are largely unknown. We hypothesized that increased RhoA/Rho-kinase signaling pathway is a major factor in the pathogenesis of age-associated ED and the mechanism involves increased penile smooth muscle contractility through inhibition of myosin light chain phosphatase.
read more

#66
Friday, 14 April 2006
Increased Nadph Oxidase-Dependent Reactive Oxygen Species Is Associated with Erectile Dysfunction in Angiotensin II-Induced Hypertensive Rats Jin. L; Leite, R; Burnett, AL; Webb, RC Department of Physiology, Medical College of Georgia, Augusta, GA; Department of Urology, Johns Hopkins Univenity, Baltimore, MD Introduction and Objectives: Hypertension is strongly associated with erectile dysfunction (ED). Inhibitors of the angiotensin II (ANG II) receptors and ANG II converting enzyme improve erectile function in both animal models and humans. However, the molecular mechanisms through which elevated ANG II may cause ED have not been investigated. We hypothesized that excessive superoxide production through up-regulation of NADPH oxidase in ANG II-induced hypertensive rats contributes to ED.
read more

#65
Friday, 14 April 2006
Corpus Cavernosum Electromyography in Patients with Vasculogenic Erectile Dysfunction Fiang, X1; Frantzen, J2; Holsheimer, F3; Wagner, G4; Wijkstra, H5; Meuleman, E2 1: Department of Urology, the Radboud University Nijmegen Medical Center, Nijmegen; 2: Department of Urology, Free University Medical Center, Amsterdam; 3: Institute for biomedical technology, University of Twente, Enschede; 4: Division of Sexual Physiology, Department of Medical Physiology, University of Copenhagen, Copenhagen; 5: Department of Urology, Academic Medical Center, Amsterdam Introduction and Objectives: Patients with vasculogenic erectile dysfunction (ED) may develop cavernous smooth muscle degeneration due to chronic cavernous hypoperfusion. To test this hypothesis, corpus cavernosum electromyography (CC-EMG) was applied to patients with and without vasculogenic ED, and the results were compared. This srudy was based on the notion that CC-EMG is a valid method to evaluate the functional state of the cavernous smooth muscle.
read more

#64
Friday, 14 April 2006
Corpus Cavernosum Electromyography in Patients with Penile Fibrosis and Patients Who Underwent Pelvic Surgery Fiang, X1; Frantzen, J2; Holsheimer, F3; Wagner, G4; Wijkstra, H5; Meuleman, E2 1: Department of Urology, the Radboud University Nijmegen Medical Center, Nijmegen; 2: Department of Urology, Free University Medical Center, Amsterdam; 3: Institute for biomedical technology, University of Twente, Enschede; 4: Division of Sexual Physiology, Department of Medical Physiology, University of Copenhagen, Copenhagen; 5: Department of Urology, Academic Medical Center, Amsterdam Introduction and Objectives: To validate corpus cavernosum electromyography (CC-EMG) as a tool for evaluating the functional state of the cavernous smooth muscle and its autonomic innervation, the CC-EMG signals of a group of men with severe ED due to penile fibrosis or cavernosal neural damage folJowing pelvic surgery were compared with the CC-EMG signals of a group of men with normal erections.
read more

#63
Friday, 14 April 2006
Reproducibility of Corpus Cavernosum Electromyography Fiang, X1; Frantzen, J2; Holsheimer, F3; Wagner, G4; Wijkstra, H5; Meuleman, E2 1: Department of Urology, the Radboud University Nijmegen Medical Center, Nijmegen; 2: Department of Urology, Free University Medical Center, Amsterdam; 3: Institute for biomedical technology, University of Twente, Enschede; 4: Division of Sexual Physiology, Department of Medical Physiology, University of Copenhagen, Copenhagen; 5: Department of Urology, Academic Medical Center, Amsterdam Introduction and Objectives: Although corpus cavernosum electromyography (CC-EMG) is used as a diagnostic tool in men with erectile dysfunction since 1989 its reproducibility has not been sufficiently assessed. The aim of this study was to assess the reproducibility of CC-EMG in healthy young men under well-controlled conditions.
read more

#62
Friday, 14 April 2006
A New Vacuum Device for Treatment for Erectile Dysfunction-a Case Study as "Proof of Principle" Humphries. AL. Jr.1; Lewis, RW1 1: Dept. Of Urology, Medical College of Georgia, Augusta, GA, USA Introduction: We describe a new device (D. S. Patent No. 6,905,459) that facilitates erectile rehabilitation.
read more

#61
Friday, 14 April 2006
Oncology Patients Referred to Psychiatry with Co-Morbid Sexual Dysfunction Hughes, MK
read more

#60
Friday, 14 April 2006
Recovering Penile Length and Erectile Function Following Radical Prostatectomy Huber, N; Wood, C; Babaian, R; Madsen, L; Shen, Y; Wen, S; Wang, R (presented by: Nelda Huber; M-PAS, PA-C)
read more

#59
Friday, 14 April 2006
Targeting Neurological Imbalances in Aging-Associated Erectile Dysfunction Hannan, FL1; Adams, MA1 1: Department of Pharmacology and Toxicology, Queen's, University, Kingston, Canada The incidence of erectile dysfunction increases with age and can be attributed to cardiovascular structural and functional alterations as well as neurological changes. Dopamine is such an important hypothalamic neurotransmitter involved in initiating erectile responses (ER) that the aging-associated imbalance in the role of this catecholamine may be a key component in the progression of erectile dysfunction. To assess whether a neurological imbalance could be pharmacologically corrected we assessed whether trazodone, a serotonin reuptake inhibitor could normalize dopamine-associated erectile responses in aged Wistar rats.
read more

#58
Friday, 14 April 2006
Recovery of Erectile Function in both Hypertensive and Normotensive Rats with Exercise and Caloric Restriction Hannan, FL1; Heaton, FPW1; Adams, MA1 1: Department of Pharmacology and Toxicology, Queen's, University, Kingston, Canada We have established that certain antihypertensive treatments can recover erectile function in spontaneously hypertensive rats (SHR) and normalize arterial pressure and penile vascular structure. In previous kidney cross-transplantation studies we established that improvements in erectile function related more to the status of the penile vasculature than to the kidney-dictated level of arterial pressure. In the present study we assessed whether increased exercise combined with caloric restriction can benefit sexual function in hypertensive and normotensive rats.
read more

#57
Friday, 14 April 2006
Role of Purinergic Receptors in the Neurogenic Response in Human Corpus Cavernosum Gur, S; Kendirci, M; Sikka, SC; Kadowitz, PF; Hellstrom, WFG Introduction and Objective: ATP, the signaling molecule of the purinergic system, is important in the initiation and maintenance of penile erection. ATP may also serve in other nonspecific systems to augment nitric oxide (NO) activity in the human corpus cavernosum (HCC). The aim of this study was to investigate whether ATP and its agonists can affect non-adrenergic non-cholinergic (NANC) relaxation responses in HCC.
read more

#56
Friday, 14 April 2006
Optimizing Nitric Oxide Production with Time-Dependent L-Arginine Administration; Inducing Relaxation in Isolated Human Corpus Cavernosum Gur, S; Kendirci, M; Kadowitz, PF; Hellstrom, WFG Introduction and Objective: This study was designed to investigate the relaxing effects of L-arginine (precursor to nitric oxide synthase [NOS]) in isolated human corpus cavernosum (HCe) and to evaluate the mechanism(s) in more detail.
read more

#55
Friday, 14 April 2006
Synchronous Prosthetic Implantation through a Trans-Scrotal Incision: A Single-Institution Outcome Analysis Gupta, S; Kendirci, M; Hellstrom, WFG Introduction and Objective: Placement of artificial urinary sphincters (AUS) and inflatable penile prostheses (IPP) are becoming more common urological procedures. Concerns of increased rates of infection and poor outcomes have limited the acceptance of simultaneous implantation of these devices. A single-institutional evaluation of dual prosthesis implantation using a single trans-scrotal approach was undertaken to determine the overall efficacy, safety, and long-term success of this innovative approach.
read more

#54
Friday, 14 April 2006
Absorption of 1 % Testosterone Gel (Testim™) from Various Application Sites Guay A; Bachand, R Introduction: Testosterone gel has become the treatment of choice for hypogonadsim because of stable levels in the normal range and the lack of skin irritation. Testim™ has shown superior blood levels but this data is limited to application of the gel to the arm and shoulder area.
read more

#53
Friday, 14 April 2006
Verapamil versus Saline in Electromotive Drug Administration (EMDA) for Peyronie's Disease: A Double-Blind Placebo-Controlled Trial Greenfield, FM1; Shab, SF1; Levine, LA1 1: Rush University Medical Center; Chicago, IL, USA Introduction: While surgery remains the "gold standard" of therapy for correction of the deformity of Peyronie's disease (PD), the search for a less invasive therapy continues. Following electromotive drug administration (EMOA) with verapamil, tunica alhuginea specimens have been demonstrated to contain detectable levels of the drug. We performed a double-blind, placebo-controlled trial to determine the effectiveness of verapamil delivered through EMDA.
read more

#52
Friday, 14 April 2006
Tadalafil Is as Efficacious in Hispanic and Black American Men with Erectile Dysfunction as in Caucasian Men: Results from Momentus (Multiple Observations in Men with ED in National Tadalafil Study in the US) Gomery, P; Bullock, A; McGettingan, J; Munarriz, R; Garcia, CS; Natanegara, F; Hague, J; G Wong, D (Presented by: Pablo Gomery, MD) Introduction and Objectives: Previous clinical studies of tadalafil have provided data primarily from Caucasian men with erectile dysfunction (ED), ≤65 years, without diabetes (DM) or a clinical diagnosis of depression (D). We conducted this study to demonstrate the efficacy of tadalafil 20 mg in Hispanic and Black American men with ED and to show that the efficacy in these groups is non-inferior to that in Caucasian men (Reference group).
read more

#51
Friday, 14 April 2006
SLx-2101, a Novel Long-Acting Phosphodiesterase-5 (PDE5) Inhibitor for Erectile Dysfunction: in vivo and in vitro Studies Sweetman, P1; Campbell, S1; Grogan, M1; Kirk, B1; McGonigle, S1; Paradise, E1; Goldstein, I1 1: Surface Logix, Inc., 50 Soldiers Field Place, Brighton, MA 02135 Introduction and Objectives: Currently marketed PDE5 inhibitors for erectile dysfunction differ in potency, speed of onset and duration of action. SLx-2101 is a novel long-acting PDE5 inhibitor that has heen designed to have excellent biochemical potency with long duration of action. In preclinical tests, SLx-2101 demonstrated excellent potency at all levels tested, i.e. molecular, cellular, ex-vivo, and in vivo. 1'harmaeokinetic studies revealed the drug to be long-lasting, maintaining therapeutic levels for greater than 24 hours in rats.
read more

#50
Friday, 14 April 2006
SLx-2101, a New Long-Acting PDE5 Inhibitor: Preliminary Safety, Tolerability, PK and Endothelial Function Effects in Healthy Subjects Prince, WT1; Campbell, AS1; Tong, W1; Sweetnam, P1; Rose, R3; Goldstein, I1; Willett, MS2; Roesch, BG2; Garcia, WD2 1: Surface Logix, Inc., Brighton, MA, USA; 2: Advanced Biomedical Research, Inc. (ABR), Hackensack, NJ, USA; 3: Robert Wood Johnson Medical School, Piscataway, NJ Introduction and Objectives: The use of PDE5 inhibitors to modify endothelial function has been established in male erectile dysfunction and pulmonary arterial hypertension. Long-acting, potent and selective PDE5 inhihitors will improve the therapeutic options for several additional indications. This study evaluated the safety, tolerahility, pharmacokinetics (PK) and pharmacodynamic effects of SLx-2101.
read more

#49
Friday, 14 April 2006
Efficacy and Safety of Tadalafil in Patients with ED and Exposure to Significant Co-Morbid Risk Factors: Results from Momentus (Multiple Observations in Men with ED in National Tadalafil Study in the US) Goldstein, I; Kim, E; Steers, WD; Pryor, JL; Wilde, DW; Natanegara, F; Wong, DG; Ahuja, S (Presented by: Irwin Goldstein, MD) Introduction and Objectives: Men with ED can have Multiple, potentially serious, Co-Morbidities (MCM). In many of these patients, ED is considered difficult to treat. We assessed the response to tadalafil 20 mg in patients with ED and a high prevalence of MCM.
read more

#48
Friday, 14 April 2006
Prevalence and Correlates of Storage, Voiding, and Mixed Male Lower Urinary Tract Symptoms: Results from the Male Attitudes Regarding Sexual Health (MARSH) Study Glasser, DB; Carson, C; Kang, J; Laumann, E
read more

#47
Friday, 14 April 2006
Identification of Key Criteria for Distinguishing between Subjects with and without Premature Ejaculation (PE) in Clinical Trials Giuliano, F1; Niederberger, CS2; Rosen, RC3; Patrick, DL4; Ho, KF5; Jamieson, C6; Gagnon, D7 1: Medical University of Paris South, Paris, France; 2: University of Illinois, Chicago, IL; 3: Robert Wood Johnson Medical School, Piscataway, NJ; 4: University of Washington, Seattle, WA; 5: ALZA Corporation, Mountain View, CA; 6: Johnson & Johnson, Mountain View, CA; 7: Johnson & Johnson, Raritan, NJ Introduction: Objective criteria for identifying men with premature ejaculation (PE) have not been established. A 4-week, multicenter, US observational study of males 218 years of age with and without PE and their female partners collected data on intravaginal ejaculatory latency time (IELT) measured using a stopwatch and several patient-reported outcome (PRO) measures that comprise the Premature Ejaculation Profile (PEP). From those data, the factors of age, IELT, and PRO measures were evaluated for their ability to accurately identify the PE population.
read more

#46
Friday, 14 April 2006
Acute Dapoxetine Delays Pudendal Motoneuron Reflex Discharges in Anesthetized Rats Giuliano F1, 2; Bernabe, J1; Gengo, P3; Laurin, M1; Clement P1 1: Pelvipharm laboratories, Campus CNRS, 91190 Gif-sur-Yvette, France; 2: Neuro-Urology unit, Department of Neurological Rehabilitation, AP-HP, Raymond Poincare Hospital, Garches, France; 3: ALZA Corporation, Mountain View, CA, USA Introduction and Objectives: Premature ejaculation (PE) is underrecognized and under-treated, despite several studies on the epidemiology of PE which indicate that this disorder is frequent and widespread. While selective serotonin reuptake inhibitors (SSRIs) are often used as pharmacotherapy for PE, the mechanism whereby they delay ejaculation is poorly understood. In the present study, the effect of acute IV dapoxetine, a new serotonin transporter inhibitor developed specifically for the treatment of PE, was evaluated in an experimental model of the ejaculatory reflex in rats—the pudendal motoneuron reflex discharges (PMRD) elicited by stimulation of the dorsal nerve of the penis (DNP).
read more

#45
Friday, 14 April 2006
Effects of a Specially Formulated Topical Alprostadil Cream by a Continuous Dosing Schedule for the Treatment of Female Sexual Arousal Disorder Gittelman, MC1; Liao, QP1; Zhang, M1; Bai, JS1; Huang, MY1; Mo, J2; Lu, M2 1: Beijing No.1 Hospital, Beijing, China; 2: NexMed, Inc. Robbinsville, NJ Introduction and Objectives: Female sexual arousal disorder (FSAD) affects both pre- and postmenopausal women and is one of the major disorders in female sexual dysfunction. Currently no approved medications for the indication of FSAD are available. The purpose of this study was to explore the enhanced therapeutic effect of a specially formulated alprostadil cream for the treatment of FSAD by comparing patient response during the first and second dosing periods.
read more

#44
Friday, 14 April 2006
Vardenafil Extended 12 Hour Data Abstract Gittelman, M
read more

#43
Friday, 14 April 2006
Long-Term Treatment with Vardenafil Reduces the Development of the Fibrotic Plaque in a Rat Model of Peyronie's Disease Ferrini, M; Kovanecz, T; Nolazco, G; Rajfer, J; Gonzalez-Cadavid, N (presented by: Monica Ferrini, PhD) Introduction and Objectives: We have previously demonstrated that long-term (45 days) continuous administration of high doses (l0mg/kg/day) of a PDE5 inhibitor, sildenafil, prevents the development of the PD-like plaque in the rat model of Pyeronie's disease (PD), through the increase of cGMP levels in the target tissues, which presumably acts as an anti fibrotic agent. In the current work we have determined whether vardenafil given orally at lower doses and different regimes, achieves a similar effect.
read more

#42
Friday, 14 April 2006
Loss of Smooth Muscle and Oxidative Stress Occur in the Rat Vagina in Diabetes, Accompanied by Inos Expression Ferrini, M; Nolauo, G; Gonzalez-Cadavid, N; Berman, J (Presented by: Monica Ferrini, PhD) Introduction and Objectives: Diabetes mellitus in women is associated with female sexual arousal disorder as manifested by decreased vaginal lubrication, and loss of compliance, that may be partially due to tissue fibrosis. Our goal was to determine in the streptozotocin diabetic rat if vaginal fibrosis is accompanied by an increase of oxidative stress and loss of smooth muscle cells, associated with inducible nitric oxide synthase expression as a putative antifibrotic factor.
read more

#41
Friday, 14 April 2006
Microvascular Arterial Bypass Surgery: Assessment of Long-term Outcome Fantini GV; Nisbet, A; Motarjem, P; Panzer, C (Presented by: Gemma Viola Fantini, MD) Introduction: Young men free of classic vascular risk factors and with pure cavernosal arterial insufficiency secondary to blunt perineal trauma are considered excellent candidates for microvascular arterial bypass surgery (MABS). This procedure has the unique ability to successfully re-establish cavernosal perfusion pressure and restore normal erectile function. There are limited long-term (> 1 year) data concerning revascularization treatment outcome in men with ED.
read more

#40
Friday, 14 April 2006
Genital Pain and Androgen Treatment: the Potential Role of Androgens in the Management of Vulvar Vestibulitis Syndrome Kung, D1; Fantini. G1; Munarriz, RR1 1: Institute for Sexual Medicine, Boston University School of Medicine Introduction: Vulvar Vestibulitis Syndrome (VVS) has been recognized as one of leading causes of genital pain in women. While controversy persists about the inflammatory/infectious/ immunologic pathophysiology of VVS, there are limited data on the hormonal dependence of human minor vestibular glandular tissue, in contrast to the established hormonal dependence of other female genital tissues. The aim of this study was to investigate the potential role of androgens in the management ofVVS in women with androgen insufficiency.
read more

#39
Friday, 14 April 2006
Relationship between Metabolic Syndrome, Erectile Dysfunction and Biomarkers of Atherosclerosis: Results from the Health Professionals Follow-up Study Eaton, CB1; Liu, YL2; Glasser; DB3; Rimm, EB2 1: Brown Medical School; 2: Harvard School of Public Health; 3: Pfizer; Inc Introduction: Erectile dysfunction (ED) is associated with several atherosclerotic risk factors that make up Metabolic Syndrome (MetS), including hypertension (HTN), dyslipidemia, glucose intolerance, and obesity. Clinical atherosclerosis is also associated with these same risk factors and with biomarkers of inflammation, thrombosis, endothelial cell activation.
read more

#38
Friday, 14 April 2006
Open Label, Multicenter, Crossover Study of Sildenafil Citrate and Tadalafil for the Treatment of Erectile Dysfunction in Patients Naïve to Phosphodiesterase 5 Inhibitor Therapy Eardley, I; Mirone, V; Montorsi, F; Kell, P; Ralph, D; Zhao, Y; Harrison, M; Beardsworth, A Introduction and Objective: To compare preference, efficacy and tolerability between sildenafil citrate (sildenafil) and tadalafil in men with erectile dysfunction (ED) naive to phosphodiesterase 5 (PDE5) inhibitor therapy.
read more

#37
Friday, 14 April 2006
The Effect of Food on the Pharmacokinetics of Dapoxetine, A New on-Demand Treatment for Premature Ejaculation Dresser, M1; Modi, NB1; Staehr, P1; Mulhall, JP2 1: ALZA C01poration, Mountain View, CA; 2: Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hwpital, New York, NY Introduction: Dapoxetine is a serotonin transporter inhibitor developed specifically for the on-demand treatment of premature ejaculation (PE). Dapoxetine has a unique pharmacokinetic profile in comparison with traditional selective serotonin reuptake inhibitors, with rapid absorption and elimination. By 24 hours after oral administration, plasma concentrations of dapoxetine are approximately 5% of peak values. This study investigated the effect of a high-fat meal on the pharmacokinetics of dapoxetine.
read more

#36
Friday, 14 April 2006
Streptozotocin-induced Diabetes Results in Time-dependent Upregulation of the Endothelin/ Rho-Kinase Pathway in Rat Corpus Cavernosum Smooth Muscle Chua, R1; Tar, M1; Melman, A1; DiSanto. ME1 1: Bronx, NY Introduction: About half of all male diabetic patients will experience erectile dysfunction (ED), with the severity of ED symptoms increasing with diabetes duration. The precise mechanism(s) whereby diabetes promotes corpus cavernosum smooth muscle (CCSM) alterations contributing to ED (i.e. Increased tone) remains unknown. Using a rat model of type I diabetes, we investigated the progression of CC (corpus cavernosum) alterations by comparing expression of proteins involved in the endothelin/Rho-kinase pathway of smooth muscle (SM) contraction at both an early and a later stage of diabetes.
read more

#35
Friday, 14 April 2006
Partial Bladder Outlet Obstruction Induces Alterations in Rat Corpus Cavernosum Smooth Muscle and Decreases in Erectile Function That Are Dependent on Duration of Obstruction Chua, R1; Tar, M1; Melman, A1; DiSanto. ME1 1: Bronx, NY Introduction: The high prevalence of erectile dysfunction (ED) in men with Lower Urinary Tract Symptoms (LUTS) suggests a pathophysiological link between LUTS and ED. To examine the association between LUTS and ED, we measured in vivo erectile function and compared expression levels of contractile proteins in rat corpus cavernosum (CC) from sham-operated rats and rats with partial bladder outlet obstruction (PBOO).
read more

#34
Friday, 14 April 2006
The Pathogenesis of Peyronie's Disease: A State of Altered Wound Healing De Young, L; Bella, A; Gan, BS; Brock, G Introduction: The true pathogenesis and natural history of Peyronie's Disease (PD) remains unclear more than 250 years since its initial description. Clinicians faced with patients affected by PD, have little scientific basis on which to provide risk of disease progression information. The formation of PD fibrotic plaques appears to be an example of abnormal wound-healing.
read more

#33
Friday, 14 April 2006
Sexual Dysfunction in Turkish Women: A Community-Based Study Demirezen, E1; Erdogan, S1 1: Istanbul University, Florence Nightingale College of Nursing, Department of Public Health Nursing, Istanbul, Turkey Introduction and Objective: Present clinical data on sexual dysfunction in Turkish women are very limited. Despite being prevalent, female sexual dysfunction (FSD) is highly underreported due to the barriers in expressing these problems which may be attributed to the traditional community structure. The aim of this study was to determine sexual problems in Turkish women at a primary health care center, and analyse the relationship with selected variables.
read more

#32
Friday, 14 April 2006
Sexual Dysfunction in Turkish Women over 40 Years of Age: A Pilot Study Demirezen, E1; Erdogan, S1 1: Istanbul University, Florence Nightingale College of Nursing, Department of Public Health Nursing, Istanbul, Turkey Introduction and Objective: Studies on female sexuality in women over 40 years of age are limited in Turkey. Misperception of relating sexuality to young population and reproductivity is an important socio-cultural barrier for the reporting of those who experience sexual problems. Considering the fact that more than 25% of the women population of Turkey is over 40 years of age, suggesting an urgent need to evaluate sexuality as a part of women health. The purpose of this study was to assess sexual dysfunction in women over 40 years of age, and evaluate related factors.
read more

#31
Friday, 14 April 2006
Ultrasound Assessment of the Penis in Peyronie's Disease Patients Dean. RC1; Lue, TF1 1: Univenity of California, San Francisco Medical Center
read more

#30
Friday, 14 April 2006
Open Label, Multicenter, Crossover Study of Sildenafil Citrate and Tadalafil in Men with Erectile Dysfunction Naïve to Phosphodiesterase 5 Inhibitor Therapy: Psychological and Interpersonal Outcomes Dean. J; Hackett, G; Gentile, V; Farina, FP; Zhao, Y; Harrison, M; Beardsworth, A Introduction and Objective: The psychological and interpersonal issues associated with erectile dysfunction (ED) and its treatment are not fully understood. In an open label crossover study comparing sildenafil citrate (sildenafil) and tadalafil in men with ED, we included assessments of preference and psychosocial factors associated with ED treatment.
read more

#29
Friday, 14 April 2006
A Novel Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Pelvic Perfusion and Symptom Scores Differ in Cardiac and Non-Cardiac Patients De. EJB; Graves, DE; Azadzoi, K; Siroky, MB; Estrera, AL; Sdringola, S; Hairston, JC; Kramer, LA; Hou, P; Westney, OL (presented by: Elise JB De, MD)
read more

#28
Friday, 14 April 2006
Demographic Characteristics and the Prevalence of Comorbid Conditions in Patients with Peyronie's Disease Davila. HH*; Garcia, JE; Broderick, G; Carrion, RE Introduction and Objective: Peyronie's disease (PD) is a fibrotic pathological condition of the penis characterized by an increase of collagen and fibrin deposition within the tunica albuginea. This condition can affect 3-9% of men. Our aims were to evaluate the demographic variables within our patients with PD and analyze the prevalence of other medical comorbidities. This may help explain whether PD is caused by both, a combination of environmental factors (trauma, aging) and mutations in multiple genes associated with a specific race and ethnicity.
read more

browse categories

Member's Section

Quick Search

Meet the Expert

Featured Conference

Editor's Corner

Resources

Services

Business of Urology

Working with Industry

Conference Reports
Sponsored By